$LSBCF News

LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders

LakeShore Biopharma Enters Into Amended Merger Agreement for Going-Private Transaction

LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company

LakeShore Biopharma Announces Receipt of Buyer Group Notice and Postponement of Extraordinary General Meeting of Shareholders

LakeShore Biopharma to Hold Extraordinary General Meeting of Shareholders

LakeShore Biopharma Enters into Definitive Agreement for Going-Private Transaction

LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq

LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee

LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company

LakeShore Biopharma Announces Fiscal Year 2025 Financial Results

LakeShore Biopharma Announces US$15 Million Private Placement Financing

LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)

LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance

LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China

LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan

Warning: LSB is at high risk of performing badly

LakeShore Biopharma Announces Leadership Transition

LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

LakeShore Biopharma Achieves Nasdaq Compliance Milestone